**1. Basics conditions**

The manuscript can be sent to the editorial office of the journal only if the following conditions are met:

* the research was conducted with the highest standards of care and conscientiousness;
* the manuscript is original and has not been published anywhere else, including by the authors of the manuscript;
* the work has not been submitted anywhere else and is not reviewed with any other publication;
* the work does not contain defamatory, defamatory or illegal statements;
* allowed to use any third-party materials;
* confirmation of consent has been obtained from all specified persons or organizations;
* authorship was agreed prior to submission, and no one was “gifted” with authorship or refused to be credited as an author (ghostly authorship).

If your research is published and we find that any of these conditions have not been met, we may take action in accordance with [COPE guidelines](https://publicationethics.org/), which may result in one of the correction notices, or we may remove or revoke the article.

Dear authors, we remind you that a scientific article must be a complete scientific study. We recommend that you do not separately publish data on the acquisition and properties/standardization of new objects (plant and synthetic) and the study of their pharmacological properties. Formally, these are parts of one study. The editors of the ScienceRise: Pharmaceutical Science journal do not accept fragments of a single study for publication. Thank you for understanding.

**Additions and additional materials**

If there are figures in the article, the authors must choose the main figure that reflects the results obtained. This figure will be placed at the title of the article in the archive of the journal.

Drawing requirements:

* format .jpg, .jpeg, .png
* resolution not less than 300 dpi
* size no more than 5 Mb

Also, electronic additional materials for the article at the request of the authors (Excel files, audio and video files) can be published.

**2. Types of articles**

*For consideration for publication in the journal ScienceRise. Pharmaceutical Science” are accepted:*

– *experimental articles*: scientific works should contain deep and high-quality innovative research, be scientifically sound and directed for use in practical pharmacy, provide important information to a wide range of domestic and international scientific societies. The experimental articles should include a theoretically sound design of the experiment, a correct interpretation of the results of the study and conclusions aimed at the practical use of the results.

– *review articles*: scientific papers should contain a critical review and a retrospective analysis of domestic and foreign literature in recent years on the subject of research on the most pressing problems of practical pharmacy. The minimum number of sources for a review article is 100.

– *short reports:* scientific works, contain research results without a detailed description of the experiment and are aimed at quickly informing about the practical result. The publication is referred to the “short messages” section at the stage of the article submission, as appropriate.

All articles must comply with the [Bioethics policy](http://journals.uran.ua/sr_pharm/bioethics).

For licensed software that was used during the study, license numbers must be indicated.

Material submitted to a “ScienceRise: Pharmaceutical Science” journal must be original and not published or submitted for publication elsewhere. This rule applies to material submitted elsewhere while the “ScienceRise: Pharmaceutical Science” journal contribution is under consideration.

**3. Requirements for the text**

**Page format** - A4, portrait

**Font** – Times New Roman

**Font size** – 14

**Interval** –1.5

**Paragraph indent** – 1.25 mm

**Alignment** - Width

**Margins of the document** – 20 mm

**Minimum number of pages** – 20

**Article language:** English

**4. Article structure**

**UDC**

**TITLE OF THE ARTICLE IN ENGLISH**

**Full name, Full Name .**... in English

Abstract in English (1800-1900 characters with spaces). In the abstract sections should be highlighted: aim, materials and methods, results, conclusions.

Keywords in English (10 words)

**The main sections of the article:**

**1. Introduction**

The introduction should provide the reader with all the information (including reference character) necessary in order to understand your research, and reasons why you hold them. In the section of the “Introduction”, it is also necessary to provide a comparison of similar pharmaceutical systems in other countries.

This section of the article, you must create background (background for the research: to provide a general understanding of the problem, which you do, and arguments to justify the relevance of your research).

The introduction should answer the question: *«What is the issue/problem is studied and why is it important?»*

This part of section of the article is to give an answer to the need for ongoing author’s research.

The argument in favor of the need for the author of the research should include detailed justification for the following two points:

1. What exactly have not been studied predecessors?

2. Why is it important to be studied?

Thus, the section of the article «Case of research» aims to highlight the outstanding part of other scientists studied the problem and point to "niche" of research, not occupied by other scientists to this problem (of course, the answers to two questions formulated above).

This section is written on the basis of periodic publications of scientific publications (books, textbooks, monographs are not related to those). Overview of periodicals on the issue should include sources of not more than 10 years ago and required a review of foreign scientific periodicals on the issue. The number of foreign sources should be at least 40 %. Permission level of self-citation is not more than 30 %. A must when using references to literary sources is a critical analysis of the data source, i.e. indication that the authors of these works have been achieved and what was not. At the same time, such analysis is desirable for each source (the use of a wide range of links such as "in the works [3-7]" is not recommended).

Section «Case of research» should give the reader an understanding of what research was conducted, the results of which the author is going to publish this article.

**ADVICE:** You can use the electronic resources of open access scientific journals around the world from [Cochrane Library](https://www.cochranelibrary.com/advanced-search?cookiesEnabled). The search can be performed by keyword of your subjects in English.

It is necessary to highlight the unresolved parts of the investigated problem by other scientists and point out the “niche” of research not occupied by other scientists in this problem.

Important! Often, as a justification for the need for an author’s study, it is indicated that the subject (question) in the scientific literature is “not described” or “not described enough”. This in no way can be considered a reasoned justification. It is not enough to refer to the fact that “this problem has not yet been studied”, because it is possible that it does not need to be studied!

**Aim of research.** The formulation of aim of the research should be performed in such a way that it became clear how to fill in the "niche" research (i.e. to answer the question: "what needs to be done to bridge the gap of knowledge associated with the presence of pieces of total problems unidentified by other scientists?»).

The aim of research, formulated by the author, can be the formulation of Hypotheses and that the author wanted to prove or disprove.

**2. Planning (methodology) of research**

The section provides the scientific justification for the selection of materials (objects), research methods and the sequence of the experiment to achieve the goal.

To plan research, authors should use the basic principles of the Quality by design concept and / or risk analysis to achieve their goals.

The design of the experiment is justified by calculations, diagrams, decision tree, etc.

**3. Materials and methods**

In this section of the article, it is necessary to describe in detail all the materials that were used in the study, indicating the source of receipt; equipment and methods (techniques) with which the research was conducted.

Materials and methods should be described in such detail that the study can be repeated.

This section should be structured in accordance with the following description of the results and their discussion.

**Studies involving animals and humans**

For research manuscripts reporting experiments on living vertebrates and / or higher invertebrates, the correspondent author must confirm that all experiments were performed in accordance with the relevant guidelines and rules. The manuscript should include a statement indicating the institutional and / or licensing committee approving the experiments, including any relevant details. Gender and other characteristics of animals that may affect results should be described. Details of housing and livestock should be included if they can affect experimental results. All animal experiments must comply with [ARRIVE](https://arriveguidelines.org/) guidelines and be conducted in accordance with the [Great Britain Animal](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/308593/ConsolidatedASPA1Jan2013.pdf) (Scientific Procedures) Act 1986 and related guidelines or [EU Directive 2010/63 / EU](http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm) on the protection of animals used for scientific purposes.

For a study in which people are participants, authors must identify a committee approving the study, ensure that the work has been carried out in accordance with the Code of Ethics of the World Medical Association ([Helsinki Declaration](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects)) and include in your manuscript a statement confirming that informed consent was obtained from all participants (recommendations for obtaining informed consent).

You can also read the Helsinki Declaration in Russian on the website of the Association of [Clinical Research Organizations](http://actorussia.org/files/WMA_Helsinki.doc).

**Clinical trial registration**

Prospective clinical trials should be registered prior to the registration of patients or in a similar public store (trials in which the main purpose is to determine pharmacokinetics are excluded).

**Human biological samples**

To describe human biological samples, we recommend that you refer to the [BRISQ](https://onlinelibrary.wiley.com/doi/full/10.1002/cncy.20147) reporting guidelines (reporting on biological samples to improve the quality of the study) and ensure that at least level 1 characteristics are provided ([link](https://onlinelibrary.wiley.com/doi/full/10.1002/cncy.20147)).

**Publication of images of participants in human subject research**

When publishing identifiable images of study participants, authors should include a statement in the published article confirming that they have received informed consent to publish the images. All reasonable measures should be taken to protect the anonymity of the patient. Black stripes above the eyes are not an acceptable means of anonymization. In some cases, we may insist on obtaining evidence of the informed consent of the authors. Images without appropriate consent will be removed from the publication.

**Studies involving human embryos, gametes, and stem cells**

Manuscripts reporting experiments involving the use of human embryos and gametes, human embryonic stem cells and related materials, as well as the clinical use of stem cells, should include confirmation that all experiments have been performed in accordance with relevant guidelines and the rules.

The manuscript should include an ethical statement that identifies the institutional and / or licensing committees that approve the experiments and describe any relevant details. A statement of ethics should also confirm that informed consent has been obtained from all recipients and / or donors of cells or tissues, where necessary, and describe the conditions of donation of research materials, such as human embryos or gametes. The editors may request copies of approved and edited consent documents.

**Experiments involving plants or microorganisms**

Experiments with plants or microorganisms taken from outside the country of the authors should have been carried out with special permission.

Botanical identity

For each cultivated medicinal plant, its botanical identity must be established and documented - scientific name (variety, species, subspecies / variety, author and family). The common name (if any) must also be indicated in the local and English languages. If necessary, other relevant information should also be indicated, including the name of the cultivar, its ecotype, chemotype and phenotype.

For cultivated plant varieties available for sale, you must specify its name, as well as the supplier. In the case of collection, breeding, distribution and cultivation of landrace in a particular region, the line should be described with its local name, indicating the sources of origin of the seed, plant or sprout material.

Selection of medicinal plants

Where appropriate, the species or botanical species that are selected for cultivation should correspond to those indicated in the national pharmacopoeia or recommended by other authoritative national documents of the country of the final consumer. In the absence of such national documents, the selection of species or botanical varieties should be based on the pharmacopoeia or other authoritative documents of other countries. In the case when medicinal plants are considered for the first time, samples or botanical varieties selected for cultivation should be defined and documented as raw materials used or described in traditional medicine of the country of origin.

**Experimental data**

Analytical data should be statistically processed using appropriate programs.

When establishing the structure of substances, the authors must provide sufficient experimental information, in particular, the available 1H and 13C NMR spectra, and X-ray crystalline structural determinations are necessary for metal complexes.

The author is responsible for presenting the correct chemical nomenclature and terminology.

An accurate description of each data set should be provided, which is shown and should include the number of biological repeats, the number of experiments performed, and a description and use of appropriate statistical methods. To verify the significance of differences in results, appropriate statistical methods should be used. The term “significant” should not be used unless a statistical analysis has been performed and the probability value used to determine significance (usually p-value) should be indicated. Manuscripts submitted without evidence of reproducibility will be rejected without formal review.

**Applications and additional materials**

Authors who wish to publish electronic supplementary materials to their article (Excel files, images, audio and video files) can send these files along with the manuscript.

**4. Result**

Results should be presented in a logical order, and it is recommended to give the results in order of importance, it is not necessary to use the order in which the experiments were conducted.

You should not duplicate the data shown in the figures, graphs and tables. A common mistake is to bring the data displayed in the figures and tables in the text of the article. Instead, the text of the article should summarize the material that the reader will find in the table or draw the reader’s attention to the main points in the figure or table. The reader, as a rule, is easier to read the data in the table than in the text of the article.

Avoid excessive figures and tables. If there is not enough data for full-fledged tables and figures, it is better to describe this information in the text.

All presented results that require repeated testing should be statistically processed. The development of analysis methods and / or technologies should be accompanied by validation characteristics.

**5. Discussion**

In this section of the article you need:

• Discuss your results in order from most to least important.

• Additional research can be proposed to improve or deepen the results.

• Compare your results with the results of other studies - how can their relevance be noted? If not, discuss the reasons for the differences. Provide a comparison of similar pharmaceutical systems in other countries. Compare your results with results from other researches – to what extent can their consistency be noted? If not, discuss the reasons for the differences.

• Describe how the results of the study can be put into practice.

• **Practical Relevance**. It is necessary to indicate exactly how the results obtained during the study can be applied in practice. The scope of application is not limited and independently distinguished by authors based on the characteristics of the study.

• **Research limitations.** A limitation is something that, in the conditions of conducting your research, is an objective reality that affects the results obtained.

• **Prospects for further research.**

**6. Conclusions**

In this section of the article, be sure to indicate once again the main summarizing results on your work, paying particular attention to the consistency of the conclusions of the aim and objectives of research. This means that the Conclusions should reflect the specific results obtained by the author, on the basis of which it is possible to draw a conclusion about the scientific novelty and the possibility of practical application of the research results presented in the article.

**Conflict of interest**

It is necessary to indicate the absence or presence of a conflict of interest. If there is a conflict of interest, it must be specified.

When there is no conflict of interest, it is necessary to specify the phrase:

The authors declare that they have no conflict of interest in relation to this research, whether financial, personal, authorship or otherwise, that could affect the research and its results presented in this paper.

**Financing**Sources of funding must be indicated. If there is no funding, it is necessary to indicate:  
The study was performed without financial support.

**Data availability**Choose one of the options and indicate it in the text of the manuscript:

* manuscript has associated data in a data repository
* manuscript has data included as electronic supplementary material
* data will be made available on reasonable request
* data cannot be made available for reasons disclosed in the data availability statement
* manuscript has no associated data

##### Use of artificial intelligence Choose one of the options and indicate it in the text of the manuscript:

* The authors confirm that they did not use artificial intelligence technologies when creating the current work.
* The authors have used artificial intelligence technologies within acceptable limits to provide their own verified data, which is described in the research methodology section.

Images, photorealistic images, diagrams, drawings, figures that have been generated by artificial intelligence should be labeled "Imagined with AI".

**Acknowledgments (if any)**

List here those people/organizations that have assisted in the course of the research (for example, provided language assistance, assistance in conducting experiments, financial assistance, etc.).

**References**

Sources are made according to [standard](https://journals.uran.ua/sr_pharm/libraryFiles/downloadPublic/1867)

**For each author:**

Full name

Scientific degree

Department

University

Address University

e-mail

Contact phone

Number of publications in Ukrainian editions (approximate)

Number of publications in international journals indexed (approximate)

H-index (if available)

ID Scopus (+ link)

Researcher ID (+ link)

ID ORCID

The author's ORCID ID is required. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

**5. Requirements for graphical abstract**

A graphical abstract is an image that appears alongside the text abstract in the contents. This is a single, concise, pictorial and visual summary of the main findings of the article.

A graphical abstract should allow readers to quickly gain an understanding of the take-home message of the paper and is intended to encourage browsing, promote interdisciplinary scholarship, and help readers identify more quickly which papers are most relevant to their research interests.

Authors must provide an image that clearly represents the work described in the paper. It could either be the superposition of several figures from the article or a figure that is specially designed for the purpose. Any postage stamps, currency from any country, or trademarked items should not be included in it. Graphical abstracts should be submitted as a separate file.

Requirements for graphical abstract:

1. Image size: the minimum required size for the graphical abstract is 560 × 1100 pixels (height × width) with minimum resolution of 300 dpi. If you are submitting a larger image, please use the same ratio. Please note that your image will be scaled proportionally to fit in the available window.
2. Font: please use font with a large enough font size as the image will be reduced in size for the table of contents to fit a window.
3. File type: .jpg, .jpeg, .png.
4. File size: no more than 5 Mb.

No additional text, outline or synopsis should be included. Any text or label must be part of the image file. Please do not use unnecessary white space or a heading “graphical abstract” within the image file.

**6. Requirements for formatting figures**

1. Before a figure, there must be a reference to the figure in the form: Fig. 1, Fig. 2‒4,   
Fig. 5, a. Before a figure, there should be a link to the figure (in the same chapter/subsection as the figure itself)

2. The caption under a figure should take the form: Fig. 1. The title of the figure.

3. If the figure consists of several subfigures, the caption should take the form: Fig. 1. The title of the figure: a ‒ the name of the first subfigure; b ‒ the name of the second subfigure...

4. If there are designations, abbreviations, or abbreviations in the figure, the transcript of which were not given earlier in the text, then those should be explained in the text under the figure. For example, the figure shows three charts, which are marked, respectively, by numbers 1, 2, and 3. Then the text under the figure should take the form: Fig. 1. Title: 1 ‒ chart 1; b ‒ chart 2; 3 ‒ chart 3.

5. Text under the figure must be part of the text.

6. Figures should be streamlined "in text."

7. The inscriptions in the figure should not be bold or sloping.

8. All inscriptions in the figure must be written in one font and one size. The exception is screenshots of programs that do not allow one to edit the font.


9. The indices in the figure should take the same form as the indices in the text.

10. On the charts, the axes' titles must be moved from the scales to the same distance of at least 0.5 cm.

11. At least one size (height or width) in the text under the figure should be the same. The horizontally located subfigures should have the same height, and the vertically located ones should have the same width.

12. Figures must be of good quality (at least 300 dpi). The inscriptions on the figures should be clear and readable, the lines of the figure should not be blurred. There should be no noise in the figure.

(We kindly ask you not to use Microsoft Paint to create or edit your drawings. This program gives a maximum of 120 dpi, which does not meet the requirements of our journal)

13. The editorial board reserves the right to reject a paper if the authors refuse to provide the original figure files to avoid data falsification (dwg ‒ for COMPAS drawings; SolidWorks, AutoCad, cdr. ‒ for CorelDRAW files; xls/xlsx ‒ for Excel, etc.).

**7. Requirements for table format**

1 Header table does not contain blank cells

2 If your document table is broken into several pages, re-do the signature on a new page does not need to!

3 All tables should be vertical (portrait orientation of the sheet in the program Word).

**8. Requirements for formatting the formulas**

1. Formulas should be typed in the MathType equation editor

2. Links to the formula in the text are (1), (2–4)

3. Formulas should be numbered

4. The formula is part of the text, so after a claim must stand semantic mark if the new sentence goes further, then the point, if further clarification is the comma

**9. Requirements for formatting the list of sources in the literature**

1. Sources must be at least 20.

2. Literature should be used mainly over the past 5-10 years. Avoid citing textbooks, reference books, popular science websites, encyclopaedias, etc. At least 70% of the used literature should be the work of foreign authors.

3. The percentage of self-citations – no more than 30%

4. References should take the form [1], [2, 3]. Hyperlinks are not allowed. The use of a wide range of references like “in [3–7]” is not allowed.

5. Links should go in order of their mention in the article.

6. All literary sources must be referenced in the text of the article.

7. The bibliographic list is issued at the end of the article according to the [standard](https://journals.uran.ua/sr_pharm/libraryFiles/downloadPublic/1867).

8. All sources must be unique (one source is mentioned only once in the bibliography).

9. All sources must be provided in the original language (i.e. if an article/book, etc. was published in Ukrainian, sources should also be added to the list of references in Ukrainian, and not a translator or transliteration should be used).

10. Before submitting the manuscript to the editor, it is necessary to check all URL sources for operability.

**REVIEWING\***

**Deadline 30–40 days**

1. Once you submit your article, it will be sent for review. Our editorial staff is practicing a double-blind peer review

*\*Review procedure involves checking for plagiarism, verification of compliance the article title and content, check the content of the article*

2. Get response from reviewers. If adjustment is then necessary to take them into account, and return an e-mail [pharm@entc.com.ua](http://pharm@entc.com.ua), [sr7508990@gmail.com](http://sr7508990@gmail.com)

3. If there are no corrections or all the remarks made by the reviewers are corrected, the article will be accepted for publication in the journal based on the results of double-blind review.

**EDITING**

Only those manuscripts that meet the standards of the journal, and fit within its aims and scope, will be sent to expert reviewers.

**Deadline 3–14 days**

1. Editing procedure involves checking articles on formal grounds, according to the correctness of the [requirements](http://journals.uran.ua/sr_pharm/about/submissions)
2. Get the answer from the editors of thejournal. If there are adjustments that need to take them into account and send the article back by email [pharm@entc.com.ua](http://pharm@entc.com.ua), [sr7508990@gmail.com](http://sr7508990@gmail.com)
3. If no adjustments or fixed all the comments made by the editor, you will need to prepare a [package of documents](http://journals.uran.ua/sr_pharm/documents)

**PACKAGE OF DOCUMENTS TO ARTICLE**

([More…](http://pharm.sr.org.ua/en/publication-terms/package-of-documents))

**HOW TO GET THE ELECTRONIC VERSION OF THE JOURNAL**

1. The electronic version of the journal can be seen in the [archive](http://journals.uran.ua/sr_pharm/issue/archive) on our site